Table 2.
Comparison of variables between participants with both baseline and 6-month follow-up values
| Domain | Data available n= | Baseline | 6-month follow-up | P value |
| Falls risk | ||||
| Fear of falling, n (%) | 40 | 0.10 | ||
| None/mild (1–2) | 8.0 (20.0) | 14.0 (35.0) | ||
| Moderate (3) | 24.0 (60.0) | 19.0 (47.5) | ||
| High (4) | 8.0 (20.0) | 7.0 (17.5) | ||
| Risk factors for falls | ||||
| Orthostatic hypotension | 104 | 24 (23.1) | 12 (11.5) | 0.002 |
| Depression | 102 | 18 (17.7) | 12 (11.8) | 0.07 |
| Proprioceptive* | 103 | 86 (83.5) | 85 (82.5) | 1.00 |
| Dizziness | 103 | 26 (25.2) | 18 (17.5) | 0.06 |
| Vasovagal symptoms or signs | 100 | 8 (8.0) | 1 (1.0) | 0.02 |
| Visual impairment | 104 | 94 (90.4) | 100 (96.2) | 0.03 |
| Hearing impairment | 101 | 64 (63.4) | 63 (62.4) | 1.00 |
| Malnutrition risk | 101 | 26 (25.7) | 25 (24.8) | 1.00 |
| Sarcopenia | ||||
| Met criteria†, n (%) | 105 | 83.0 (78.3) | 79.0 (74.5) | 0.51 |
| Biochemical measures (IQR) | ||||
| Albumin (g/L) | 54 | 43 (41–45) | 42 (40–44) | 0.046 |
| Corrected calcium (mmol/L) | 41 | 2.4 (2.3–2.4) | 2.4 (2.3–2.4) | 0.31 |
| Creatinine (nmol/L) | 54 | 80 (70–90) | 80 (70–95) | 0.46 |
| eGFR (mL/min) | 54 | 65.5 (56, 78) | 64 (54–82) | 0.22 |
| Hb (g/L) | 53 | 132 (126–142) | 132 (127–143) | 0.30 |
| Vitamin D (nmol/L) | 51 | 63 (48–78) | 65 (54–83) | 0.32 |
| PTH (pmol/L) | 43 | 6.9 (4.2–9.5) | 6.6 (4.7–10.8) | 0.48 |
| TSH (mlU/L) | 44 | 1.5 (0.9–2.0) | 1.6 (0.8–2.1) | 0.15 |
Bold p values indicate significant difference between baseline and 6-month follow-up measures.
*Proprioceptive and vestibular abnormalities.
†
Sarcopenia criterion is fulfilling at least two of the following criteria: gait velocity <0.8 m/s, grip strength <20 kg (females) and <30 kg (males) and appendicular lean mass/height2<5.5 kg/m2 (females) or <7.26 kg/m2 (males).
BMD, bone mineral density (femoral neck); eGFR, estimated glomerular filtration rate; Hb, haemoglobin; PTH, parathyroid hormone; TSH, thyroid-stimulating hormone.